End-of-day quote
Other stock markets
|
||
- USD | - |
08/05 | Lexaria Bioscience Corp. Begins Dosing of Its Second Glp-1 Human Pilot Study | CI |
16/04 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
Sales 2024 * | 6L 4.96Cr | Sales 2025 * | 5L 4.06Cr | Capitalization | 4.05Cr 337.01Cr |
---|---|---|---|---|---|
Net income 2024 * | -50L -42Cr | Net income 2025 * | -70L -58Cr | EV / Sales 2024 * | 67.9 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 83 x |
P/E ratio 2024 * |
-6.83
x | P/E ratio 2025 * |
-7.06
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.23% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 26/06/26 | |
John Docherty
PSD | President | 53 | 15/15/15 |
George Jurcic
IRC | Investor Relations Contact | - | 01/21/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 26/06/26 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 08/11/08 |
Albert Reese
BRD | Director/Board Member | 74 | 14/21/14 |
1st Jan change | Capi. | |
---|---|---|
+32.36% | 69TCr | |
+29.97% | 59TCr | |
-1.60% | 37TCr | |
+20.07% | 33TCr | |
+6.04% | 29TCr | |
+14.43% | 24TCr | |
+10.27% | 21TCr | |
-3.39% | 21TCr | |
+9.27% | 17TCr |